Citations

Clear

3942 citation(s) found for "To, Van".

The epigenetic reader Brd4 is required for osteoblast differentiation
Paradise, Christopher R. , Galvan, M. Lizeth, Kubrova, Eva , Bowden, Sierra , Liu, Esther, Carstens, Mason F. , Thaler, Roman , Stein, Gary S. , Wijnen, André J. van , Dudakovic, Amel , Carstens, Mason , van Wijnen, Andre J , Stein, Gary S , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | December 23, 2019 | Volume: 235 | Issue: 6 | Pages: 5293-5304

10.1002/jcp.29415 | PMID 31868237 Get It

AbstractTranscription networks and epigenetic mechanisms including DNA methylation, histone modifications, and noncoding RNAs control lineage commitment of multipotent mesenchymal progenitor cells. Proteins that read, write, and erase histone tail modifications curate and interpret the highly intricate histone code. Epigenetic reader proteins that recognize and bind histone marks provide a crucial link between histone modifications and their downstream biological effects. Here, we investigate the role of bromodomain‐containing (BRD) proteins, which recognize acetylated histones, during osteogenic differentiation. Using RNA‐sequencing (RNA‐seq) analysis, we screened for BRD proteins (n = 40) that are robustly expressed in MC3T3 osteoblasts. We focused functional follow‐up studies on Brd2 and Brd4 which are highly expressed in MC3T3 preosteoblasts and represent “bromodomain and extra terminal domain” (BET) proteins that are sensitive to pharmacological agents (BET inhibitors). We show that small interfering RNA depletion of Brd4 has stronger inhibitory effects on osteoblast differentiation than Brd2 loss as measured by osteoblast‐related gene expression, extracellular matrix deposition, and alkaline phosphatase activity. Similar effects on osteoblast differentiation are seen with the BET inhibitor +JQ1, and this effect is reversible upon its removal indicating that this small molecule has no lasting effects on the differentiation capacity of MC3T3 cells. Mechanistically, we find that Brd4 binds at known Runx2 binding sites in promoters of bone‐related genes. Collectively, these findings suggest that Brd4 is recruited to osteoblast‐specific genes and may cooperate with bone‐related transcription factors to promote osteoblast lineage commitment and maturation.
Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families
Yang, Xin , Doroszuk, Alicja, Schneider, Sandra , Allen, Jamie , Decker, Brennan , Redman, James , Scarth, James A. , Plaskocinska, Inga, Luccarini, Craig , Shah, Mitul , Pooley, Karen A. , Dorling, Leila , Lee, Andrew , Adank, Muriel A. , Aittomäki, Kristiina, Andrulis, Irene L. , Ang, Peter , Bernstein, Jonine L. , Bobolis, Kristie, Borg, Åke , Blomqvist, Carl , Claes, Kathleen , Cuggia, Adeline , Culver, Julie O. , Damiola, Francesca , Pauw, Antoine De , Dolinsky, Jill S. , Engel, Christoph , Evans, D. Gareth , Goode, Ellen L. , Gruber, Stephen B., Hahnen, Eric , Hake, Christopher R., Heikkinen, Tuomas , Hurley, Judith , Janavičius, Ramūnas , Kleibl, Zdeněk , Kleiblová, Petra , Konstantopoulou, Irene , Kvist, Anders , LaDuca, Holly , Lee, Ann S. G. , Lesueur, Fabienne , Mannermaa, Arto, Manoukian, Siranoush , McFarland, Rachel, McKinnon, Wendy, Meindl, Alfons , Metcalfe, Kelly , Taib, Nur Aishah Mohd , Moilanen, Jukka S. , Nathanson, Katherine L. , Ng, Pei Sze , Nguyen‐Dumont, Tú , Nielsen, Sarah M. , Obermair, Florian , Offit, Kenneth, Olopade, Olufunmilayo I. , Ottini, Laura , Penkert, Judith , Pylkäs, Katri , Ramus, Susan J. , Rudaitis, Vilius , Side, Lucy, Silva‐Smith, Rachel , Silvestri, Valentina , Skytte, Anne‐Bine , Slavin, Thomas, Soukupová, Jana , Trainer, Alison H., Unzeitig, Gary, Usha, Lydia , Hansen, Thomas van Overeem , Whitworth, James , Wood, Marie , Yip, Cheng Har , Yoon, Sook‐Yee , Yussuf, Amal , Zogopoulos, George , Goldgar, David E. , Chenevix‐Trench, Georgia , George, Sophia , Houdayer, Claude , James, Paul A. , El-Haffaf, Zaki, Ehrencrona, Hans , Janatová, Markéta , Peterlongo, Paolo , Nevanlinna, Heli, Schmutzler, Rita K., Teo, Soo‐Hwang , Weitzel, Jeffrey N. , Elliott, Aaron , Winqvist, Robert , Easton, Douglas F. , Antoniou, Antonis C. , Houdayer, Claude , James, Paul , Lesueur, Fabienne , Peterlongo, Paolo , Ramus, Susan J , Teo, Soo H , Weitzel, Jeffrey N , Claes, Kathleen B M , Ehrencrona, Hans , Evans, D Gareth , Konstantopoulou, Irene , Olopade, Olufunmilayo I , Silvestri, Valentina , Nathanson, Katherine L , Engel, Christoph , Nguyen-Dumont, Tu , Chenevix-Trench, Georgia , Ottini, Laura , Metcalfe, Kelly A , Pylkäs, Katri , Janatova, Marketa , Soukupova, Jana , Hansen, Thomas van Overeem , Kleibl, Zdenek , Manoukian, Siranoush , Mohd Taib, Nur Aishah , Decker, Brennan , Leslie, Goska , Dunning, Alison M. , Adlard, Julian , Barwell, Julian , CONCANNON, PATRICK J. , Dı́ez, Orland , Domchek, Susan M. , Fostira, Florentia , Garber, Judy E. , Golmard, Lisa , Maher, Eamonn R. , Mannermaa, Arto, Meindl, Alfons , Neuhausen, Susan L. , Radice, Paolo , Slavin, Thomas P. , Tondini, Carlo Alberto , Hopper, John L. , Pharoah, Paul D.P. , Balmañà, Judith , El-Haffaf, Zaki, Nevanlinna, Heli , Robson, Mark E. , Pal, Tuya , Couch, Fergus J. , Southey, Melissa C. , Foulkes, William D. , Tischkowitz, Marc D.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2019 | Volume: 38 | Issue: 7 | Pages: 674-685

10.1200/jco.19.01907 | PMID 31841383 Get It

PURPOSETo estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized.METHODSWe analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes.RESULTSWe found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10−76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10−3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10−3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10−2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age ( P for trend = 2.0 × 10−3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies ( P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.CONCLUSIONThese results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
Veer, Rozanne C. de , Thorburn, Douglas , Janssen, Harry L.A. , Lindor, Keith D. , Parés, Albert , Floreani, Annarosa , Mayo, Marlyn J. , Nevens, Frederik , Ponsioen, Cyriel Y. , Buuren, Henk R. van , van der Meer, Adriaan J , Harms, Maren H. , Lammers, Willem J. , Corpechot, Christophe , Trivedi, Palak Jitendrakumar , Hirschfield, Gideon M. , Invernizzi, Pietro , Battezzati, Pier Maria , Mason, Andrew L. , Kowdley, Kris V. , Hansen, Bettina E.

Mayo Clinic

Gut | December 16, 2019 | Volume: 69 | Issue: 8 | Pages: 1502-1509

10.1136/gutjnl-2019-319057 | PMID 31843787 Get It

Objective The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC. Methods The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group database. Results We included 3902 patients with a median follow-up of 7.8 (4.1–12.1) years. The overall HR of UDCA was 0.46 (95% CI 0.40 to 0.52) and the 5-year LT-free survival without UDCA was 81% (95% CI 79 to 82). The NNT to prevent one LT or death within 5 years (NNT5y) was 11 (95% CI 9 to 13). Although the HR of UDCA was similar for patients with and without cirrhosis (0.33 vs 0.31), the NNT5y was 4 (95% CI 3 to 5) and 20 (95% CI 14 to 34), respectively. Among patients with low alkaline phosphatase (ALP) (≤2× the upper limit of normal (ULN)), intermediate ALP (2–4× ULN) and high ALP (>4× ULN), the NNT5y to prevent one LT or death was 26 (95% CI 15 to 70), 11 (95% CI 8 to 17) and 5 (95% CI 4 to 8), respectively. Conclusion The absolute clinical efficacy of UDCA with respect to LT or death varied with baseline prognostic characteristics, but was high throughout. These findings strongly emphasise the incentive to promptly initiate UDCA treatment in all patients with PBC and may improve patient compliance.
Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
Marcath, Lauren A. , Vangipuram, Kiran, Gersch, Christina L. , Rae, James M. , Burness, Monika L. , Griggs, Jennifer J. , Poznak, Catherine Van , Hayes, Daniel F. , Henry, N. Lynn , Beutler, Andreas S. , Hertz, Daniel L. , Hertz, Daniel L , Henry, N Lynn , Kidwell, Kelley M. , Lavoie Smith, Ellen M

Mayo Clinic

British Journal of Clinical Pharmacology | December 11, 2019 | Volume: 86 | Issue: 5 | Pages: 880-890

10.1111/bcp.14192 | PMID 31823378 Get It

AimsChemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold).MethodsGermline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8‐item sensory subscale (CIPN8) of the patient‐reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN‐related treatment disruption.ResultsEPHA5 rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β‐coefficient = 0.39, 95% confidence interval 0.11–0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild‐type (13.6 h) patients. Total number of missense variants (median = 0, range 0–2) was associated with decreased PN sensitivity (β‐coefficient: −0.42, 95% confidence interval −0.72 to −0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683.ConclusionIsolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Abramson, Vandana G. , Sanders, Melinda E. , Mayer, Erica L. , Haddad, Tufia C. , Nanda, Rita , Poznak, Catherine Van , Storniolo, Anna Maria , Nangia, Julie R. , González-Ericsson, Paula I. , Johnson, Kimberly N., Chen, Sheau‐Chiann , Shyr, Yu , Arteaga, Carlos L. , Pietenpol, Jennifer A. , Abramson, Vandana G , Sanders, Melinda E , Mayer, Erica L , Gonzalez-Ericsson, Paula I , Abramson, Richard G , Chen, Sheau-Chiann , Wolff, Antonio C , Lehmann, Brian David , Sanchez, Violeta M. , Wolff, Antonio C.

Mayo Clinic

Clinical Cancer Research | December 10, 2019 | Volume: 26 | Issue: 9 | Pages: 2111-2123

10.1158/1078-0432.ccr-19-2170 | PMID 31822498 Get It

Abstract Purpose: Preclinical data demonstrating androgen receptor (AR)–positive (AR+) triple-negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition catalyzed an investigator-initiated, multi-institutional phase Ib/II study TBCRC032. The trial investigated the safety and efficacy of the AR-antagonist enzalutamide alone or in combination with the PI3K inhibitor taselisib in patients with metastatic AR+ (≥10%) breast cancer. Patients and Methods: Phase Ib patients [estrogen receptor positive (ER+) or TNBC] with AR+ breast cancer received 160 mg enzalutamide in combination with taselisib to determine dose-limiting toxicities and the maximum tolerated dose (MTD). Phase II TNBC patients were randomized to receive either enzalutamide alone or in combination with 4 mg taselisib until disease progression. Primary endpoint was clinical benefit rate (CBR) at 16 weeks. Results: The combination was tolerated, and the MTD was not reached. The adverse events were hyperglycemia and skin rash. Overall, CBR for evaluable patients receiving the combination was 35.7%, and median progression-free survival (PFS) was 3.4 months. Luminal AR (LAR) TNBC subtype patients trended toward better response compared with non-LAR (75.0% vs. 12.5%, P = 0.06), and increased PFS (4.6 vs. 2.0 months, P = 0.082). Genomic analyses revealed subtype-specific treatment response, and novel FGFR2 fusions and AR splice variants. Conclusions: The combination of enzalutamide and taselisib increased CBR in TNBC patients with AR+ tumors. Correlative analyses suggest AR protein expression alone is insufficient for identifying patients with AR-dependent tumors and knowledge of tumor LAR subtype and AR splice variants may identify patients more or less likely to benefit from AR antagonists.
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
Venneker, Sanne , Kruisselbrink, Alwine B. , Jong, Yvonne de, Wijnen, André J. van , Danen, Erik H.J. , Bovée, Judith V.M.G. , van Wijnen, Andre J , Danen, Erik H J , Bovée, Judith V M G , Bruijn, Inge H. Briaire‐de

Mayo Clinic

Cancers | December 3, 2019 | Volume: 11 | Issue: 12 | Pages: 1918

10.3390/cancers11121918 | PMID 31810230 Get It

Chondrosarcomas are chemo- and radiotherapy resistant and frequently harbor mutations in isocitrate dehydrogenase (IDH1 or IDH2), causing increased levels of D-2-hydroxyglutarate (D-2-HG). DNA repair defects and synthetic lethality with poly(ADP-ribose) polymerase (PARP) inhibition occur in IDH mutant glioma and leukemia models. Here we evaluated DNA repair and PARP inhibition, alone or combined with chemo- or radiotherapy, in chondrosarcoma cell lines with or without endogenous IDH mutations. Chondrosarcoma cell lines treated with the PARP inhibitor talazoparib were examined for dose–response relationships, as well as underlying cell death mechanisms and DNA repair functionality. Talazoparib was combined with chemo- or radiotherapy to evaluate potential synergy. Cell lines treated long term with an inhibitor normalizing D-2-HG levels were investigated for synthetic lethality with talazoparib. We report that talazoparib sensitivity was variable and irrespective of IDH mutation status. All cell lines expressed Ataxia Telangiectasia Mutated (ATM), but a subset was impaired in poly(ADP-ribosyl)ation (PARylation) capacity, homologous recombination, and O-6-methylguanine-DNA methyltransferase (MGMT) expression. Talazoparib synergized with temozolomide or radiation, independent of IDH1 mutant inhibition. This study suggests that talazoparib combined with temozolomide or radiation are promising therapeutic strategies for chondrosarcoma, irrespective of IDH mutation status. A subset of chondrosarcomas may be deficient in nonclassical DNA repair pathways, suggesting that PARP inhibitor sensitivity is multifactorial in chondrosarcoma.
Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group
Seligman, William , Das‐Gupta, Zofia , Jobi-Odeneye, Adedayo O. , Arbelo, Elena , Banerjee, Amitava , Caffrey-Armstrong, Bridget , Cehic, D. , Corbalán, Ramón , Collins, Michael , Dandamudi, Gopi, Dorairaj, Prabhakaran, Fay, Matthew , Gelder, Isabelle C. Van , Goto, Shinya , Granger, Christopher B. , Gyorgy, Bathory , Hendriks, Jeroen , Hills, Mellanie True , Hobbs, Richard , Koplan, Kate , Lane, Deirdre A. , Lewis, William R. , Lobban, Trudie , Moseley, S. Kelley, Camm, A. John , Granger, Christopher B , Arbelo, Elena , Banerjee, Amitava , Hobbs, F D Richard , Hendriks, Jeroen M , Lane, Deirdre A , Bollmann, Andreas , Collins, Michael , Dorairaj, Prabhakaran, Healey, Jeff S. , Huisman, Menno Volkert , Steinberg, Benjamin A. , McLeod, Christopher J. , Timmis, Adam , Guo, Yutao

Mayo Clinic

European Heart Journal | December 2, 2019 | Volume: 41 | Issue: 10 | Pages: 1132-1140

10.1093/eurheartj/ehz871 | PMID 31995195 Get It

Abstract Aims As health systems around the world increasingly look to measure and improve the value of care that they provide to patients, being able to measure the outcomes that matter most to patients is vital. To support the shift towards value-based health care in atrial fibrillation (AF), the International Consortium for Health Outcomes Measurement (ICHOM) assembled an international Working Group (WG) of 30 volunteers, including health professionals and patient representatives to develop a standardized minimum set of outcomes for benchmarking care delivery in clinical settings. Methods and results Using an online-modified Delphi process, outcomes important to patients and health professionals were selected and categorized into (i) long-term consequences of disease outcomes, (ii) complications of treatment outcomes, and (iii) patient-reported outcomes. The WG identified demographic and clinical variables for use as case-mix risk adjusters. These included baseline demographics, comorbidities, cognitive function, date of diagnosis, disease duration, medications prescribed and AF procedures, as well as smoking, body mass index (BMI), alcohol intake, and physical activity. Where appropriate, and for ease of implementation, standardization of outcomes and case-mix variables was achieved using ICD codes. The standard set underwent an open review process in which over 80% of patients surveyed agreed with the outcomes captured by the standard set. Conclusion Implementation of these consensus recommendations could help institutions to monitor, compare and improve the quality and delivery of chronic AF care. Their consistent definition and collection, using ICD codes where applicable, could also broaden the implementation of more patient-centric clinical outcomes research in AF.
Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare
Hampel, Paul J. , Call, Timothy G. , Ding, Wei , Kenderian, Saad S. , Leis, José F., Witzig, Thomas E. , Koehler, Amber B. , Fonder, Amie , Schwager, Susan M., Rabe, Kari G. , Dyke, Daniel L. Van , Braggio, Esteban , Kenderian, Saad Sirop , Witzig, T.E. , Fonder, Amie L, Chaffee, Kari G. , Van Dyke, Daniel L, Parikh, Sameer A , Ding, Wei , Braggio, Esteban , Muchtar, Eli , Wang, Yucai , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

American Journal of Hematology | December 2, 2019 | Volume: 95 | Issue: 3 | Pages: No page available

10.1002/ajh.25690 | PMID 31788844 Get It

Modernizing Storage Conditions for Fresh Osteochondral Allografts by Optimizing Viability at Physiologic Temperatures and Conditions
Denbeigh, Janet M. , Paggi, Carlo Alberto , Resch, Zachary T., Bagheri, Leila, Mara, Kristin C. , Arani, Arvin , Zhang, Chenghao , Saris, Daniël B.F. , Krych, Aaron J. , Wijnen, André J. van , Paggi, Carlo A, Mara, Kristin, Krych, Aaron J , van Wijnen, Andre J , van Wijnen, Andre J , Arani, Arvin , Mara, Kristin C , Hevesi, Mario , Larson, A. Noelle

Mayo Clinic

CARTILAGE | November 28, 2019 | Volume: 13 | Issue: 1_suppl | Pages: 280S-292S

10.1177/1947603519888798 | PMID 31777278 Get It

Objective. Osteochondral allograft (OCA) transplantation has demonstrated good long-term outcomes in treatment of cartilage defects. Viability, a key factor in clinical success, decreases with peri-implantation storage at 4°C during pathogen testing, matching logistics, and transportation. Modern, physiologic storage conditions may improve viability and enhance outcomes. Design. Osteochondral specimens from total knee arthroplasty patients (6 males, 5 females, age 56.4 ± 2.2 years) were stored in media and incubated at normoxia (21% O 2 ) at 22°C or 37°C, and hypoxia (2% O 2 ) at 37°C. Histology, live-dead staining, and quantitative polymerase chain reaction (qPCR) was performed 24 hours after harvest and following 7 days of incubation. Tissue architecture, cell viability, and gene expression were analyzed. Results. No significant viability or gene expression deterioration of cartilage was observed 1-week postincubation at 37°C, with or without hypoxia. Baseline viable cell density (VCD) was 94.0% ± 2.7% at day 1. At day 7, VCD was 95.1% (37°C) with normoxic storage and 92.2% (37°C) with hypoxic storage ( P ≥ 0.27). Day 7 VCD (22°C) incubation was significantly lower than both the baseline and 37°C storage values (65.6%; P < 0.01). COL1A1, COL1A2, and ACAN qPCR expression was unchanged from baseline ( P < 0.05) for all storage conditions at day 7, while CD163 expression, indicative of inflammatory macrophages and monocytes, was significantly lower in the 37°C groups ( P < 0.01). Conclusion. Physiologic storage at 37°C demonstrates improved chondrocyte viability and metabolism, and maintained collagen expression compared with storage at 22°C. These novel findings guide development of a method to optimize short-term fresh OCA storage, which may lead to improved clinical results.
Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)
Baretella, Oliver , Blaise, Gilbert, Bond, Richard A. , Cai, Yin , Chan, C K, Chataigneau, Thierry, Chen, M., Chen, Hui , Cheng, Yanhua, Clément, Denis, Cohen, Richard A. , Collis, Michael J., Detremmerie, Charlotte Marie Simonne, Félétou, Michel, Flavahan, Nicolas, Gao, Yuansheng, Guo, Yumeng , Hoeffner, U., Houston, Donald S., Huang, Ianto Boscheng, Huang, Yü , Iliano, Stephane, Junquéro, Didier, Katušić, Zvonimir S. , Komori, Kimihiro , Lee, Mary Y. K. , Leung, Susan W.S. , Li, Zhuo-ming, Liang, Sophie Chaofan, Liu, J, Lüscher, Thomas F. , Michel, Frederic, Miller, Virginia M. , Mombouli, Jean-Vivien, Morrison, Keith , Muldoon, Sheila M., O’Rourke, Steve, Perrault, Louis P. , Quignard, Jean‐François , Rusch, Nancy J. , Sánchez‐Ferrer, Carlos F. , Shen, Kaikai , Shi, Yi , Song, Erfei , Sun, Kiwi W.Y., Tang, Eva Hoi Ching, Tuncer, Meral , Ende, Romana van den, Vedernikov, Yuri P., Verbeuren, Tony J., Webb, Clinton, Wong, Kenneth H.K., Xu, Cheng , Yang, Kangmin , Zellers, Thomas M. , Zhao, Yingzi , Zou, Qian , fellows, on behalf of Professor Paul M. Vanhoutte’s former, Boulanger, Chantal M. , Collis, Michael, Danser, A.H. Jan , Mey, Jo G. R. De , Duprez, Daniel , Huang, Ianto Bosheng , Michel, Frederic, Schini‐Kerth, Valérie B. , Shi, Yi, Taddei, Stefano , Tang, Eva H.C., Weigert, André Luiz Loureiro , Wong, Kenneth K. H., Ying, Fan, Shimokawa, Hiroaki , fellows, on behalf of Professor Paul M. Vanhoutte’s former

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 39 | Issue: 12 | Pages: 2445-2447

10.1161/atvbaha.119.313461 | PMID 31770032 Get It